Please login to the form below

Not currently logged in
Email:
Password:

NICE revises Victoza recommendation

NICE has released a revised preliminary recommendation for Novo Nordisk's Victoza (liraglutide) for patients with type 2 diabetes

The National Institute for Health and Clinical Excellence (NICE) has released a revised preliminary recommendation on the use of Novo Nordisk's once-daily injectable human GLP-1 analogue Victoza (liraglutide) for patients with type 2 diabetes. The revised recommendation maintains the positioning issued in February 2010 and includes the recommendation that Victoza is a clinically and cost-effective treatment option under certain circumstances. 

These circumstances are that liraglutide 1.2mg daily is used in combination with one oral anti-diabetic tablet (metformin or a sulphonylurea) for treatment in patients with type 2 diabetes, if:

• they are intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and

• they are intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.

The release of the revised recommendation follows a second appraisal committee meeting held in April, and final guidance is expected by October this year. Novo Nordisk will continue dialogue with NICE regarding patient groups that could benefit from liraglutide 1.8mg and to support the use of liraglutide in line with the licence it was granted in June 2009 by the European Medicines Agency (EMA, formerly EMEA).

14th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics